Clinical Trials Browser

OTHER × Sunitinib × Genitourinary × Clear all

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Urologic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00715442 2025-12-23

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04394975 2025-11-28

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase 3 Completed

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

NCT07165418 2025-09-10

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT00930033 2025-09-05

CARMENA

Phase 3 Completed

Carcinoma, Renal Cell

NCT06222593 2025-02-17

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT01254864 2025-01-27

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Phase 2 Completed

190 enrolled 9 charts

Prostatic Neoplasms

NCT03109015 2024-10-08

ASSET

Phase 2 Completed

7 enrolled 18 charts

Carcinoma, Renal Cell

NCT03905889 2024-06-25

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1 Terminated

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01517243 2023-09-21

Phase II Study of Alternating Sunitinib and Temsirolimus

Phase 2 Completed

37 enrolled 13 charts

Carcinoma, Renal Cell

NCT06032728 2023-09-13

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Phase NA Not yet recruiting

Carcinoma, Renal Cell

NCT05816642 2023-04-18

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Phase NA Unknown

Carcinoma, Renal Cell

NCT00520533 2022-10-12

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1 Terminated

8 enrolled 18 charts

Carcinoma, Renal Cell, Mycobacterium Infections, Nontuberculous

NCT01061411 2022-08-05

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

Carcinoma, Renal Cell

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02689167 2021-11-29

SURF

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT02959554 2021-09-08

NIVOSWITCH

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00853125 2021-04-27

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Phase 2 Terminated

10 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02960906 2021-04-26

BIONIKK

Phase 2 Completed

Clear-cell metastatic renal cell carcinoma

NCT00541008 2021-02-21

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02555748 2021-01-12

SUP-R

Phase 4 Completed

Carcinoma, Renal Cell

NCT03066427 2020-11-13

INMUNOSUN

Phase 2 Completed

Carcinoma, Renal Cell

NCT02060370 2020-02-27

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Phase 2 Completed

60 enrolled 13 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms

NCT03571438 2020-01-18

COMBOREIN

Phase NA Unknown

Kidney Neoplasms

NCT03379012 2019-10-22

FARETES

Phase 2 Completed

Carcinoma, Renal Cell

NCT00794950 2019-09-23

Sutent

Phase 2 Completed

43 enrolled 10 charts

Urinary Bladder Neoplasms

NCT03519542 2019-09-18

SOGANG

Carcinoma, Renal Cell

NCT01118351 2019-05-01

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Phase 2 Terminated

19 enrolled 11 charts

Urinary Bladder Neoplasms

NCT00526656 2019-04-16

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

Phase 2 Completed

9 enrolled 5 charts

Urinary Bladder Neoplasms

NCT01502228 2019-03-05

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Phase NA Terminated

14 enrolled 7 charts

Carcinoma, Renal Cell

NCT01731158 2019-02-06

BERAT

Phase 2 Completed

Carcinoma, Renal Cell

NCT03323710 2019-01-09

Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Carcinoma, Renal Cell

NCT01158222 2018-09-14

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 2 Completed

37 enrolled 9 charts

Carcinoma, Renal Cell

NCT03456401 2018-03-07

TOKIO

Phase 2 Terminated

Carcinoma, Renal Cell

NCT01499121 2018-03-06

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Phase 2 Completed

Clear-cell metastatic renal cell carcinoma

NCT01042795 2017-06-28

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Phase 2 Terminated

7 enrolled 5 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00537056 2017-06-14

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Phase NA Completed

17 enrolled 6 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00425386 2017-05-03

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Completed

60 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02071641 2017-04-07

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

Phase 2 Terminated

Carcinoma, Renal Cell

NCT00879619 2017-02-01

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Phase 1/2 Terminated

4 enrolled 3 charts

Prostatic Neoplasms

NCT02446795 2017-01-18

QUASAR

Phase 1/2 Unknown

Carcinoma, Renal Cell, Fatigue, Kidney Neoplasms

NCT00943839 2016-11-10

Sunitinib Malate in Treating Patients With Kidney Cancer

Phase NA Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01803503 2016-06-22

Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors

Phase 2 Unknown

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Stomach Neoplasms